Largest Shareholder Hyeonho Jeong Increases Medy-Tox Stake by 1,315 Shares via Open Market Purchase and Modifies Pledge Agreements - Minimal Dilution with Credible Counterparties
Hyeonho Jeong CEO and largest shareholder of Medy-Tox increased his stake by 1,315 shares through open market purchases on June 23 and 24, 2026, raising his ownership from 18.63% to 18.65%.
The acquisition cost of approximately 99.91 million KRW was fully funded from his own capital, with purchase prices of 75,924 KRW and 77,000 KRW per share.
Existing stock-backed loans with Shinhan Investment Securities were extended, and a new loan was arranged with Korea Securities Finance by pledging an additional 127,372 shares, bringing total pledged shares to 248,105.
[AI Summary]This report reflects a minor increase in the largest shareholder's stake and modifications to pledge agreements, with no dilution from new share issuance. Counterparty risk is low due to the high creditworthiness of Shinhan Investment and Korea Securities Finance. While the direct impact on stock price is limited, the additional purchase by the largest shareholder can be interpreted as a positive signal for management stability.